SUMMARY
patients so that their rest would be less disturbed and provide better analgesia. It has, however, been observed with morphine that supplementing PCA with an infusion did not reduce the number of demands made by patients. I ()"12 This study was undertaken to assess the effect of supplementing alfentanil PCA with a background infusion and to determine whether the infusion altered the MEC.
PATIENTS AND METHODS The study was approved by the hospital's Human Ethics Committee. Patients scheduled to undergo major upper abdominal surgery and aged between 18 and 70 years, weighing between 50 and 100 kg, who were ASA 1 or 2, not receiving analgesic agents or steroids and with normal liver function were eligible for inclusion. On the night before surgery, after written informed consent was obtained, patients were tutored in the use of PCA. Patients were then allocated by lottery to one of four postoperative pain therapies utilizing alfentanil, such that ten patients received each therapy: I. 200 mcg demand bolus, 2. 300 mcg demand bolus, 3. 100 mcg demand bolus plus 900 mcglh continuous infusion, 4 . 200 mcg demand bolus plus 900 mcg/h continuous infusion, all with a five-minute lockout interval.
The bolus dose sizes of 100-300 mcg were chosen on the basis of previous studies using alfentanil PCA. 9 An infusion rate of 900 mcg/h was used, as our earlier results 9 indicated that this would provide a blood alfentanil concentration of approximately 40 ng/ml. These alfentanil doses were not scaled according to body weight as a previous studyl3 has shown alfentanil clearance to be relatively independent of body weight.
A standardised anaesthetic technique was used. Premedication was with oral diazepam; anaesthesia was induced with a titrated dose of propofol plus alfentanil 75-100 mcglkg. Tracheal intubation was facilitated by vecuronium and the lungs were artificially ventilated with 70% N 2 0 in 30% 02 to an end-tidal C02 of between 4.0 and 4.6 kPa. Anaesthesia was maintained with an infusion of alfentanil supplemented by enflurane titrated between 0.6 and 1.5% inspired concentration. Alfentanil was infused at a rate of 0.75-1.00 mcg/ kg/minute until thirty minutes before the end of surgery, at which time, ifthe patient was to receive only PCA, the infusion was ceased, and if the patient was to receive PCA plus an infusion, the rate of administration was reduced to 0.25 mcglkg/ min. This infusion rate was designed to provided a steady state plasma concentration of around 40 ng/ml. The Bard Harvard Mini Infuser was used to control the opioid infusion during surgery.14 At the end of surgery residual neuromuscular blockade was reversed by neostigmine administered with atropine and the patient was transferred to the recovery room and connected to a Graseby PCAS device programmed to deliver the assigned alfentanil dose regimen. Patients were unaware to which treatment group they had been assigned.
For the next 24 hours, pain, sedation, respiratory rate, number of demands and dose of alfentanil received were recorded every hour by ward nursing staff who were otherwise not involved in the study. Pain was measured using a 10 cm visual linear analogue (VLA) slide rule scale lS and sedation was assessed using a previously described sedation scale where 0 = none (alert), 1 = mild (occasionally drowsy, easy to arouse), 2 = moderate (frequently drowsy, easy to arouse), 3 = severe (somewhat, difficult to arouse), and S = sleeping (normal sleep, easy to arouse). 16 For each patient the time integrals of pain (pain-AUC) and sedation (sedation-AUC) were calculated by the trapezoidal rule. Time-points at which the patient was asleep were excluded. If a patient described pain control as inadequate or had a VLA greater than 4 cm for two consecutive hours or had a respiratory rate of less than 8 per minute, it was considered that the PCA prescription was unsatisfactory for that patient. In these cases, PCA was discontinued and the patient was withdrawn from the study.
The alfentanil was infused in parallel to the maintenance intravenous fluids through an antireflux valve system and a sampling cannula was placed in the contralateral forearm. Patients were asked by one of the investigators or the research assistant to indicate when more analgesic was required so that a blood sample could be obtained immediately prior to a demand. The blood was deep frozen in lithium-heparin tubes until assayed by gas-liquid chromatography using nitrogenphosporus detection. 9 Numbers of patients withdrawn from PCA plus infusion and PCA only groups were compared using a chi-square test. Differences among the four treatment groups for continuous variables (alfentanil blood concentrations, alfentanil dose, pain-AUC, sedation-AUC) were assessed by one factor analysis of variance. If a significant (P < 0.05) difference was found, PCA only and PCA plus infusion groups were compared by constructing a linear contrast. 17
RESULTS
All patients had surgery performed through an upper abdominal incision. The groups were similar with respect to age, weight and operation ( Table 1) .
The majority of patients obtained satisfactory postoperative pain control and completed the study (Table 2 ). There were no significant differences either between the two groups receiving PCA only or between the two groups receiving PCA plus infusion. There were, however, differences apparent between groups receiving PCA and groups receiving PCA plus infusion. Seven patients receiving PCA only and two receiving PCA plus infusion were withdrawn due to inadequate pain control (0.1 > P> 0.05). Three patients in the PCA plus infusion groups but only one receiving PCA only were withdrawn because of respiratory depression. Only patients with complete data sets (not withdrawn) were included in subsequent analyses.
In patients in whom complete data were available, i.e. those not withdrawn, the addition of the background infusion to PCA appeared to reduce the number of demands made (Figure 1) but this was not statistically significant (P> 0.05). Patients who received an infusion received significantly more alfentanil (P< 0.01) than the PCA only groups (Figure 2 ). Blood alfentanil concentration data were not obtained for three patients;in the others concentrations were measured immediately prior to 2-6 demands. Initially (0-12 h) there were no differences in mean blood alfentanil concentrations among the groups, but from 12-24 h the groups receiving PCA plus infusion had achieved a significantly higher (P < 0.05) mean blood drug concentration ( Figure   3 ). Despite the extra drug received and the consequently higher blood concentrations patients receiving PCA plus infusion did not have significantly lower pain-AUC (Figure 4 ) or higher sedation-AUC ( Figure 5 ). Only limited data were available for those patients who were withdrawn because the PCA prescription was inadequate for them. Table 3 shows mean dose of alfentanil received and mean blood alfentanil concentrations in patients withdrawn due to inadequate pain control and those not withdrawn during the period 4-8 hr after initiation of PCA, when data were available for .... most patients. Patients withdrawn due to inadequate pain relief received more alfentanil and had higher blood alfentanil concentrations than those not withdrawn, suggesting that they had a higher MEC and were unable to maintain it. It is doubtful whether the measured blood concentrations in these patients reflect their actual MECs as pain relief was presumably inadequate at these concentrations. Nevertheless, the patients who were withdrawn showed similar trends to those not withdrawn, those assigned to PCA plus infusion receiving a higher dose and having higher blood alfentanil concentrations.
DISCUSSION
In this study using alfentanil, the co-administration of a fixed-rate infusion with PCA did not proportionately reduce the number of demands made by patients. This resulted in more drug being received and in a higher mean blood alfentanil concentration in those patients receiving PCA plus infusion than in patients prescribed PCA alone. In other studies of PCA using morphine, it had been observed that the demand dose and background infusion prescribed are major factors in determining the dose of drug received.lO-12.14.18
.... .... These data are not consistent with a relationship existing between blood opioid concentration and analgesic response but suggest that when the MEC is determined by PCA, the prescription may influence the result. Since administering more drug results in a higher MEC, the MEC is only of predictive value when the drug is to be administered under the same conditions as when the MEC was ascertained. Why the fixed-rate infusion apparently led to a higher MEC is unclear.
The mean MEC in the PCA only groups was similar to that obtained in a previous study9 and is consistent with data obtained by Chapman et at.
where mean alfentanil plasma concentrations of 40-90 ng/ml produced a significant decrease in (experimental) pain. 19 Lehmann et al. have reported the MEC for alfentanil (measured in plasma by radioimmunoassay) to be 15 ng/ml, 8 although the distribution of values was lognormally distributed and ranged from 0.6 to 99 ng/ml. These patients had, however, received other opioids for anaesthesia which may have reduced their postoperative requirements.
Pain control in patients who completed the study was similar among all groups, although the groups receiving an infusion as well as PCA received more alfentanil. However, fewer patients receiving PCA plus infusion complained of inadequate analgesia than in the PCA only groups but the corollary was that these patients were more likely to develop respiratory depression. Thus, the provision of extra drug beyond that demanded by patients may shift the balance towards more successful pain relief, but at the cost of a need for improved respiratory monitoring.
In a comparison of PCA and PCA plus infusion after caesarean section, it was noted that the hybrid therapy significantly reduced movement-related pain. 2o However, although this should have an impact on the speed of recovery by promoting deep breathing and ambulation there was a much higher incidence of nausea and vomiting which required treatment than in the PCA only group, again suggesting a compromise between desired effect and side-effects when using a background infusion with PCA. It has previously been reported that there is little sedation associated with postoperative analgesia by alfentanil. 9 There were no differences in sedation between the groups in this study even though the groups receiving infusions received significantly more drug. Investigation of alfentanil in the management of cancer pain, where it would be advantageous to have an opioid analgesic that would provide pain control without sedation, could be of value.
In this study we have confirmed that alfentanil PCA can be an effective method of controlling postoperative pain. A view commonly held is that patients receiving PCA will demand sufficient opioid to maintain their blood concentration above their MEC. If that were the case, addition of a background infusion would contribute to the blood concentration and lower the demand rate proportionately. Our results indicate that either this view is incorrect, or that in the case of alfentanil the analgesic drug prescription is one of the determinants of the MEC.
